MedPath

HemaQuest Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Private, Subsidiary
Established
2007-01-01
Employees
11
Market Cap
-
Website
https://www.hemaquest.com

Clinical Trials

8

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:4
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (50.0%)
Phase 2
4 (50.0%)

Effects of HQK-1001 in Patients With Sickle Cell Disease

Phase 2
Terminated
Conditions
Sickle Cell Disease
Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin S Disease
Sickling Disorder Due to Hemoglobin S
Interventions
Drug: Placebo
First Posted Date
2012-05-18
Last Posted Date
2015-03-18
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
77
Registration Number
NCT01601340
Locations
🇺🇸

University of South Alabama, Mobile, Alabama, United States

🇺🇸

Children's Hospital and Research Center - Oakland, Oakland, California, United States

🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

and more 15 locations

A Study of HQK-1001 in Patients With Sickle Cell Disease

Phase 2
Completed
Conditions
Sickle Cell Disease
Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin S Disease
Sickling Disorder Due to Hemoglobin S
Interventions
First Posted Date
2011-03-24
Last Posted Date
2013-06-19
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
52
Registration Number
NCT01322269
Locations
🇺🇸

Children's Hospital and Research Center - Oakland, Oakland, California, United States

🇺🇸

University of Miami Miller School of Medicine - Dept of Pediatrics, Miami, Florida, United States

🇺🇸

Georgia Health Sciences University - Adult SIckle Cell Center, Augusta, Georgia, United States

and more 13 locations

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Phase 2
Terminated
Conditions
Lymphoid Malignancies
Lymphoproliferative Disorders
Interventions
First Posted Date
2009-10-09
Last Posted Date
2011-08-01
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
1
Registration Number
NCT00992732
Locations
🇺🇸

LPCH/Stanford, Palo Alto, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 5 locations

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Phase 2
Terminated
Conditions
EBV Lymphomas
Lympho-proliferative Diseases
Interventions
First Posted Date
2009-06-10
Last Posted Date
2011-08-01
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
1
Registration Number
NCT00917826
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Phase 1
Completed
Conditions
Sickle Cell Disease
Interventions
Drug: Placebo
First Posted Date
2009-02-12
Last Posted Date
2011-08-01
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
24
Registration Number
NCT00842088
Locations
🇺🇸

Trialogic Research, Madison, Alabama, United States

🇺🇸

Children's Hospital and Research Center at Oakland, Oakland, California, United States

🇺🇸

Century Clinical Research, Inc., Daytona Beach, Florida, United States

and more 6 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.